AI-generated analysis. Always verify with the original filing.
Relmada Therapeutics reported audited financial results for the full year and fourth quarter ended December 31, 2025, with a full year net loss of $57.4 million and provided a corporate update including positive 12-month Phase 2 data for NDV-01 showing 95% complete response rate at any time and 76% at 12 months in high-risk NMIBC, a $160 million PIPE financing, and plans to initiate Phase 3 RESCUE program mid-2026.
Event Type
Disclosure
Mandatory
Variant
8-K
by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K, including the inform
by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including the inform
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1* Press release dated March 19, 2026, regarding corporate update and full year 202
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $57.40 | GAAP |
| Net Loss per Basic and Diluted Share | $1.45 | GAAP |